19 suspended. 19 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Suspended 19 |
| Phase 1 | 7 | Suspended 7 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-12 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma T3011 + Cobimetinib - Melanoma, Malignant Melanoma | Phase 2 | Suspended | ImmVira Pharma Co. Ltd | 68 | 2024-06-30 | 2024-02-01 |
| Methimazole in Patients With Progressive Glioblastoma Methimazole, Recurrent Glioblastoma Surgical Resection, Pharmacodynamic Assays - Glioblastoma, Glioma | Phase 2 | Suspended | Case Comprehensive Cancer Center | 19 | 2023-01-30 | 2026-11-17 |
| A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS) - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma | Phase 2 | Suspended | SonALAsense, Inc. | 15 | 2022-08-12 | 2024-09-19 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| Neoadjuvant T-VEC in High Risk Early Melanoma T-Vec - Melanoma | Phase 2 | Suspended | University of California, Davis | 6 | 2020-05-21 | 2023-09-15 |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 1 / Phase 2 | Suspended | Roswell Park Cancer Institute | 47 | 2018-01-31 | 2026-07-15 |
| Efficacy of Propranolol Treatment to Prevent Melanoma Progression Propranolol hydrochloride, Placebo pill - Stages III Skin Melanoma, Stages II Skin Melanoma | Phase 2 | Suspended | University Hospital, Geneva | 450 | 2016-06-01 | 2019-05-10 |
| A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) Antineoplaston therapy (Atengenal + Astugenal) - Diffuse, Intrinsic Pontine Glioma | Phase 2 | Suspended | Burzynski Research Institute | 1 | 2016-04-13 | 2025-09-16 |
| A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours [177]Lu-DOTA-TATE - Carcinoma, Neuroendocrine | Phase 2 | Suspended | AHS Cancer Control Alberta | 413 | 2014-04-29 | 2026-07-27 |
| Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma TPI 287, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Suspended | Cortice Biosciences, Inc. | 92 | 2013-08-01 | 2023-02-22 |
| Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Bevacizumab and Carboplatin - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Suspended | Northwell Health | 54 | 2011-09-01 | 2026-06-01 |
| Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery sargramostim, paclitaxel - Melanoma (Skin) | Phase 2 | Suspended | University of Virginia | 42 | 2005-07-01 | 2013-12-10 |
| Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma autologous dexosomes loaded with tumor-specific peptides - Melanoma | Phase 2 | Suspended | Anosys | 60 | 2002-07-01 | 2005-06-24 |
| Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2 M40403 - IL-2 Induced Hypotension | Phase 1 / Phase 2 | Suspended | MetaPhore Pharmaceuticals | 48 | 2001-12-01 | 2005-06-24 |
| Biological Therapy in Treating Patients With Primary or Advanced Glioma aldesleukin, lymphokine-activated killer cells - Brain and Central Nervous System Tumors | Phase 2 | Suspended | Weill Medical College of Cornell University | 1997-07-01 | 2009-02-09 |
Melanoma (8) · Glioblastoma (6) · Brain Neoplasms (3) · Diffuse Intrinsic Pontine Glioma (3) · Glioma (3) · Astrocytoma (2) · Carcinoma, Neuroendocrine (2) · Neoplasms (2) · Recurrence (2) · Carcinoma, Renal Cell (1) · Central Nervous System Neoplasms (1) · Ependymoma (1) · Gliosarcoma (1) · Hodgkin Disease (1) · Hypotension (1)
Neoplasms by Histologic Type (19) · Neoplasms, Germ Cell and Embryonal (19) · Neoplasms, Nerve Tissue (18) · Neoplasms (17) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (12) · Neuroendocrine Tumors (10) · Neoplasms, Neuroepithelial (9) · Nevi and Melanomas (8) · Skin Diseases (8) · Skin Neoplasms (8) · Skin and Connective Tissue Diseases (8) · Brain Diseases (6) · Central Nervous System Diseases (6)
Bevacizumab (3) · Biopsy (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Propranolol (2) · Specimen Handling (2) · pembrolizumab (2) · CA-4948 (1) · Carboplatin (1) · Disulfides (1) · Lomustine (1) · Methimazole (1) · Paclitaxel (1) · Radiosurgery (1)
AHS Cancer Control Alberta (1) · Anosys (1) · Burzynski Research Institute (1) · Case Comprehensive Cancer Center (1) · Cortice Biosciences, Inc. (1) · ImmVira Pharma Co. Ltd (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · MetaPhore Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · NaviFUS Corporation (1) · Northwell Health (1) · Roswell Park Cancer Institute (1) · SonALAsense, Inc. (1) · University Hospital, Geneva (1)
United States (16) · Canada (1) · Switzerland (1)
Arvind Nageshwara Dasaru, MD (1) · Bently Doonan, MD, MS (1) · Cameron Gaskill, MD (1) · Corina Andresen, MD (1) · David Peereboom, MD (1) · Eric M Thompson, M.D. (1) · J. P. Duic, M.D. (1) · Jian Campian, M.D. (1) · John Boockvar, MD (1) · Louis B. Nabors, III, M.D. (1) · Michael C Lowe, MD (1) · Michael Lim (1) · Nimish Mohile, M.D. (1) · Pierre Giglio, M.D. (1)
R01CA296813 (1), R44CA261516 (1), U10CA180821 (1)